Last reviewed · How we verify
MYDAYIS
mydayis works by interacting with a specific target in the body to produce a desired effect.
mydayis is a small molecule developed by NYU Langone Health, but its target, drug class, and approved indications are unknown. As a small molecule, it is a type of medication that can be taken orally and is typically made up of a single compound. The commercial status of mydayis is unclear, and it is owned by NYU Langone Health. There is limited information available on its safety considerations, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the full scope of mydayis.
At a glance
| Generic name | MYDAYIS |
|---|---|
| Also known as | d-amphetamine / l-amphetamine |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells have locks on them, and mydayis has a key that fits into those locks. When the key (mydayis) binds to the lock, it sends a signal that tells the cell to do something, like make a certain protein or block a certain process. This is a simplified explanation of how mydayis works at a molecular level.
Approved indications
Boxed warnings
- WARNING: ABUSE, MISUSE, AND ADDICTION MYDAYIS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing MYDAYIS, assess each patient’s risk for abuse, misuse, and addiction. Educate
Common side effects
- Insomnia
- Decreased appetite
- Dry mouth
- Decreased weight
- Heart rate increased
- Anxiety
- Nausea
- Abdominal pain upper
- Irritability
- Weight decreased
- Headache
- Blood pressure increased
Serious adverse events
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Anaphylaxis
- Angioedema
- Hypersensitivity reactions
Key clinical trials
- AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
- 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression (PHASE2)
- Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening (PHASE3)
- The Reinforcing Mechanisms of Smoking in Adult ADHD (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MYDAYIS CI brief — competitive landscape report
- MYDAYIS updates RSS · CI watch RSS
- NYU Langone Health portfolio CI